CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 619 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Dexmedetomidine 0.6 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04111926
NCT04111926Phase 4Completed
CompareCT.gov

Impact of Intraoperative Dexmedetomidine on Long-term Outcomes in Elderly Patients After Major Non-cardiac Surgery: 3-year Follow-up of a Randomised Controlled Trial

Peking University First Hospital·interventional·Posted Oct 1, 2019·Updated Apr 20, 2022

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine and Placebo for Overall Survival. Completed, enrolled 619 participants across 1 site.

Detailed Summary

This is a 3-year follow-up of patients enrolled in a previous randomized controlled trial which showed that intraoperative dexmedetomidine reduced delirium in elderly patients after major non-cardiac surgery. The purpose of this study is to clarify the effects of intraoperative dexmedetomidine on long-term outcomes of these patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverall Survival
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedOct 1, 2019
Enrollment StartOct 7, 2019
Primary CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.8 years ago

Interventions

Dexmedetomidinedrug

A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.

Placebodrug

Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.